May 1st 2024
The combination of pembrolizumab, trastuzumab, and chemotherapy showed significant improvement in overall survival vs placebo in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Integrating a geriatric assessment into the care of older adults who are receiving cancer treatment in communi­ty oncology practices improves patient and caregiver satisfaction and encourages commu­nication about aging-related concerns, accord­ing to results of a clinical trial that enrolled 541 patients with advanced cancer.
Read More
Telehealth Delivers Access to Care and Cutting-Edge Clinical Research to Rural Areas
January 11th 2020The present and future benefits of telehealth in oncology can be observed through Tahoe For­est Cancer Center and its affiliation with the UC Davis Cancer Center, use of other remote clinics, and participation in virtual tumor boards. Even though there are roadblocks to telehealth reaching more locations and more patients, the potential benefit warrants the time needed to get over those hurdles.
Read More
FDA Grants Fast Track Designation to Infigratinib for First-Line Treatment of Cholangiocarcinoma
January 6th 2020Infigratinib has been granted Fast Track Designation by the FDA for the treatment of cholangiocarcinoma in adult patients with first-line advanced or metastatic disease, according to a press release from QED Therapeutics, a subsidiary of BridgeBio Pharma, Inc, and developer of infigratinib.
Read More
Aiding Immune Responses Through CXCR4 Inhibition in Patients With Pancreatic Cancer
January 6th 2020In an interview with Targeted Oncology at the 2019 Ruesch Symposium, Fearon, professor, Weil Cornell Medicine, discussed his presentation on the CXCL-12 pathway, which can exclude T cells from pancreatic ductal adenocarcinoma. He also shared his opinion on how to advance the treatment landscape in the future.
Read More
Experts Reflect on the Most Impactful FDA Moves of 2019
January 4th 2020The FDA granted approval to countless treatments across cancer types throughout 2019 until the end of the year, with a final approval on December 31<sup>st </sup>for the first BRCA targeted therapy in pancreatic cancer. Following the excitement for a new year of further advances, Targeted Oncology followers on Twitter shared their thoughts on some of the most impactful FDA approvals in 2019.
Read More
Body Mass Index May Be A Determinant of OS in Patients with Clear Cell Renal Cell Carcinoma
January 3rd 2020Individuals with obesity who were diagnosed with locally advanced or metastatic clear cell renal cell carcinoma achieved longer overall survival than patients of normal weight in select groups of an independent cohort study, which evaluated overall survival and the transcriptomic differences in the primary tumor and peritumoral adipose tissue in adult patients with metastatic clear cell renal cell carcinoma.
Read More
Results from a phase II prospective trial indicate that fluorouracil-, leucovorin-, irinotecan-, and oxaliplatin-based treatment and imaging-based biomarkers for borderline resectable pancreatic ductal adenocarcinoma achieved a resection rate of 45% and a median overall survival of 2 years.<br />
Read More
ODAC Recommends Olaparib as First-Line Maintenance for Germline BRCA-Mutated Pancreatic Cancer
December 18th 2019In a 7-to-5 vote, the FDA’s Oncologic Drugs Advisory Committee recommended the PARP inhibitor olaparib as first-line maintenance therapy for patients with germline BRCA-mutated metastatic pancreatic cancer whose disease did not progress after first-line treatment with platinum-based chemotherapy, AstraZeneca and MSD, Inc. reported in a press release.<br />
Read More
KEYNOTE-164 Update: Pembrolizumab Provides Durable Responses in Patients With MSI-H/dMMR CRC
December 13th 2019New results from the KEYNOTE-164 trial have shown that patients with previously treated microsatellite instability-high DNA mismatch repair advanced or metastatic colorectal cancer who received pembrolizumab responded well to the drug.
Read More
FDA Schedules Hearing to Discuss Olaparib for BRCA-Mutant Metastatic Pancreatic Cancer
December 6th 2019The FDA Oncologic Drugs Advisory Committee has announced a hearing to discuss a supplemental new drug application for olaparib tablets <a>for the maintenance treatment of adult patients with deleterious or suspected deleterious germline <em>BRCA-</em>mutant metastatic pancreatic adenocarcinoma</a> who have not progressed on first-line platinum-based chemotherapy.
Read More
A Look Back at FDA News from November 2019
December 2nd 2019In November 2019, the FDA approved a number of treatments, including acalabrutinib for the treatment of chronic lymphocytic leukemia and small lymphocytic leukemia, as well as zanubrutinib for the treatment of mantle cell lymphoma. A biosimilar for pegfilgrastim was also approved under indications.
Read More
MRTX849 Shows Safety, Tolerability in Treating KRAS G12C
November 29th 2019In patients whose solid<strong> </strong>tumors harbor a mutation in <em>KRAS </em>G12C, therapy with MRTX849 has produced promising responses and acceptable toxicity across 3 tumors types, according to data presented at the 2019 American Association for Cancer Research–National Cancer Institute–European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics.
Read More
Pemigatinib Granted Priority Review by FDA for Treatment of Cholangiocarcinoma
November 27th 2019The FDA has granted a priority review designation to a New Drug Application for pemigatinib, as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements, according to a press release from Incyte.
Read More
FGFR2 Emerges as a Promising Target in Cholangiocarcinoma
November 20th 2019Given the frequency of <em>FGFR2</em> alterations in intrahepatic cholangiocarcinoma, investigators have identified it as a potential prognostic indicator of survival and a rational target of systemic cancer therapies.
Read More
FDA Grants Orphan Drug Designation to TT-00420 for Treatment of Cholangiocarcinoma
November 8th 2019TT-00420, an investigational spectrum-selective multiple kinase inhibitor received an orphan drug designation from the FDA for the treatment of cholangiocarcinoma, TransThera Biosciences Co. Ltd announced in a press release.
Read More
Determining the Optimal Timing for Immunotherapy in Patients With GEJ Cancers
November 1st 2019Daniel Catenacci, MD, discusses how he makes decisions with immunotherapeutic agents for the treatment of patients with gastroesophageal junction cancer. He says he bases his sequencing decisions on a number of factors.
Watch
Differences in Prognoses for Patients With Right-Sided or Left-Sided Colorectal Cancer
October 25th 2019Scott Kopetz, MD, PhD, explains how prognoses for patients with colorectal cancer differ based on whether their cancer is left-sided or right-sided and discusses how knowledge of these differences have led to the development of more agents to treat both groups of patients.
Watch
Onvansertib Show Early Signals of Safety and Efficacy in KRAS-Mutated mCRC
October 23rd 2019The combination of onvansertib, a third-generation adenosine triphosphate inhibitor, with FOLFIRI and bevacizumab achieved positive responses in patients with metastatic colorectal cancer in the second-line setting, according to the results of a phase Ib/II reported in a press release from Trovagene, Inc.<br />
Read More
FDA Approves New Aprepitant Dosing Regimen for CINV After MEC
October 23rd 2019The FDA has approved a supplemental New Drug Application for a single dose of aprepitant injectable emulsion for intravenous use in patients receiving moderately emetogenic chemotherapy. The approval expands the dose for aprepitant to include a 130 mg single-dose regimen for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.<br />
Read More